T1DM is an autoimmune disease in which T cells attack and destroy the insulin-producing β cells in the pancreatic islets. Immunotherapies are treatments that reprogram the immune system so that it no longer attacks and destroys insulin-producing β cells in the pancreas. Ace Therapeutics can provide immunotherapy development service T1DM with more efficient function analysis.
Type 1 diabetes mellitus (T1DM) is a chronic, immune-mediated disease leading to destruction of pancreatic β cells, which produce insulin under normal circumstances. The development of β cell autoantibodies is induced after exposure of a genetically susceptible individual to an environmental factor, a process which triggers immune response. Destruction of β cells leads to a decrease in insulin secretion, development of hyperglycemia, and ultimately clinically overt T1DM.
Model of Stages of T1DM (Alvin, C. P. The Journal of Clinical Investigation. 2021)
The immune pathogenesis of T1DM begins with a breakdown in self-tolerance that leads to a T-cell mediated destruction of β-cells. Classical characteristics of this autoimmune disease include the presence of autoantibodies (AAbs) specific for β-cells antigens and insulitis.
Mechanisms of Immune Tolerance and Therapeutics in T1DM (Jeremy, T. W.; et al. Cell Metabolism. 2019)
Immunotherapies for T1DM have focused on restoration of tolerance, T cell or B cell inhibition, regulatory T cell (Treg) induction, suppression of innate immunity and inflammation, immune system reset, and islet transplantation.
| Immunotherapies | Description |
|---|---|
| Pro-inflammatory cytokine inhibition strategy | Pro-inflammatory cytokines, such as IL-1β, IL-6, ΤΝF-α are involved in the pathogenesis of T1DM, playing an important role in recruiting immune cells to the inflammation site and interfering with cell transcription and translation pathways via specific inflammatory networks. |
| Cell immunotherapeutic | immunomodulatory approaches directed at B lymphocytes, T lymphocytes, regulatory T cells by anti-CD3, anti-CD20, CTLA-4Ig, anti-CD2. |
| Autoantigen-specific immunotherapeutic | Antigen-specific interventions can suppress autoimmune response and avoid the off-target effects seen with systemic immunomodulating therapies. |
With years of experience in therapy development, Ace Therapeutics can provide the T1DM immunotherapy development services for our clients. Our services include but not limited to the followings.
Developing combination therapies by combining immunotherapies with other therapies to improve efficacy.
Highly Customizable
One-stop Services
High Quality
Professional Team
Ace Therapeutics offers cost-effect and high-quality research services related to T1DM immunotherapy development for our clients worldwide. Our assays are developed and processed with the highest standard and the results are delivered on time without compromising quality. Please feel free to contact us.
